NCT01684150: A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving |
|
|
| Completed | 1 | 51 | Europe, US | EPZ-5676 | Epizyme, Inc., Celgene | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders | 11/15 | 02/16 | | |
